Variability in drug efficacy and safety is a leading challenge in chemotherapeutics
Substantial variation exists in oncology treatment in a given population, resulting in unpredictable responses and potentially deadly adverse events (AEs). Chemotherapeutic AEs often are much more severe than in other therapeutics.1 Adding to the complexity of cancer therapeutic evaluation are the contributions to drug efficacy and safety from both acquired (somatic) and inherited (germline) variations.
Help predict a patient’s medical and pharmaceutical response
Germline pharmacogenomics is an important tool in helping understand how patients metabolize medications based on their DNA. It can help clinicians:
EVALUATE associations between drug efficacy, toxicity, and variation in drug-metabolizing enzymes, and transporters2
OPTIMIZE individual-specific treatment efficacy, and administer the appropriate chemotherapy agent at the right dosage while minimizing adverse events1